levodopa methyl ester

RN given refers to parent cpd(L)-isomer

Also Known As:

L-dopa methyl ester; dl-dopa methyl ester; dopa methyl ester, (D)-isomer; levodopa methyl ester hydrochloride; levodopa methyl ester hydrochloride, (DL)-isomer; melevodopa; methyl L-dopa

Networked: 32 relevant articles (1 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stocchi, Fabrizio: 6 articles (12/2019 - 01/2007)
2.	Huang, Renbin: 3 articles (04/2021 - 02/2012)
3.	Li, Rong: 3 articles (04/2021 - 02/2012)
4.	Liang, Tao: 3 articles (04/2021 - 02/2012)
5.	Marconi, Stefano: 3 articles (01/2015 - 07/2010)
6.	Chen, Zhaoni: 2 articles (04/2021 - 09/2013)
7.	Lin, Xing: 2 articles (04/2021 - 09/2013)
8.	Zhang, Shijun: 2 articles (04/2021 - 09/2013)
9.	Vacca, Laura: 2 articles (12/2019 - 01/2015)
10.	Cai, Yunpeng: 2 articles (01/2012 - 09/2011)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 04/01/2011 - "Aim of the present study was to evaluate the clinical efficacy, tolerability and quality-of-life measures to melevodopa in advanced Parkinson's disease (PD) with motor fluctuations (MFs). " 01/01/1992 - "Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease." 04/01/1991 - "Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease." 07/01/1987 - "Levodopa methyl ester treatment of Parkinson's disease." 12/01/2019 - "We have performed a systematic literature review to evaluate the current evidence of the pharmacokinetic (PK), efficacy and safety profile of oral melevodopa/carbidopa fixed combination in the management of motor fluctuations in patients with Parkinson disease (PD). "
2.	Dyskinesias (Dyskinesia) 12/01/2019 - "Although they differed in used dose regimens, duration of treatment and endpoints, the results of the efficacy/safety studies suggest that treatment with melevodopa/carbidopa may determine improvements in motor fluctuations compared to treatment with standard LD/CD formulations, with no increased risk of adverse effects or LD-induced dyskinesias. " 01/01/2022 - "doses of l-Dopa methyl ester plus benserazide) using a controlled blinded protocol to assess motor disability, l-DOPA -induced dyskinesias (LID), and other neurologic drug effects. " 01/01/2012 - "Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats." 09/15/2011 - "Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats." 07/01/2010 - "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)."
3.	Amblyopia (Lazy Eye) 02/06/2012 - "Therefore this study assessed the anatomic and physiologic effects of 30 days' treatment of l-dopa methyl ester at different doses on visual cortex area 17 in feline model with amblyopia induced by monocular vision deprivation. " 04/20/2021 - "Corrigendum to "l-Dopa methyl ester attenuates amblyopia-induced neuronal injury in visual cortex of amblyopic cat" [Gene 527 (2013) 115-122]." 09/15/2013 - "L-dopa methyl ester attenuates amblyopia-induced neuronal injury in visual cortex of amblyopic cat." 02/06/2012 - "Effects of l-dopa methyl ester on visual cortex injury induced by amblyopia and its underlying mechanism." 02/06/2012 - "The results suggest that l-dopa methyl ester can effectively inhibit amblyopia process via a mechanism that may involve increasing endogenous NGF expression and promoting neural repairment in visual cortex area 17."
4.	Infections 07/01/2014 - "Future studies that evaluate the usefulness of melevodopa beyond the acute challenge (eg, using motor diaries) in patients with gastrointestinal infections are warranted."
5.	Melanoma (Melanoma, Malignant) 09/15/1988 - "Compounds 1 and 2 exhibited greater potency and selectivity against malignant melanoma than did the natural product L-DOPA methyl ester." 09/15/1988 - "Compound 2 was active in 6 of 10 melanoma and 0 of 5 nonmelanoma cell lines while both Compound 1 and L-DOPA methyl ester were active in 1 of 10 melanomas and 0 of 5 nonmelanomas. " 08/01/1978 - "L-dopa methyl ester has been shown to be an effective antitumor agent against the B-16 melanoma in vivo. " 01/01/1996 - "These results show that in vivo Tyr and Phe restriction improves the therapeutic response of a metastatic variant of B16-BL6 (BL6) murine melanoma to adriamycin (ADR) and B16 melanoma to levodopa methyl ester. " 05/01/1983 - "These data indicate that adding ascorbate and restricting tyrosine and phenylalanine in combination with levodopa methyl ester therapy may become an important strategy for treating malignant melanoma."

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	levodopa drug combination benserazide
3.	Solutions
4.	Carbidopa (Lodosyn)
5.	levodopa methyl ester
6.	Tablets
7.	Prodrugs
8.	Benserazide
9.	alpha-Methyltyrosine (Metirosine)
10.	sirio

Related Therapies and Procedures

1.	Duration of Therapy
2.	Therapeutics
3.	Aftercare (After-Treatment)